Company news

Supernus Pharmaceuticals, Inc. news in 2022

Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

November 21, 2022

Supernus to Present at Two November Healthcare Conferences

November 7, 2022

Supernus Announces Third Quarter 2022 Financial Results

November 7, 2022

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

October 24, 2022

Supernus Provides Regulatory Update on SPN-830

October 9, 2022

Supernus to Present at the 2022 Wells Fargo Healthcare Conference

August 30, 2022

Supernus Announces Second Quarter 2022 Financial Results

August 3, 2022

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 24, 2022

Supernus Announces First Quarter 2022 Financial Results

May 8, 2022

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

May 1, 2022

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

May 1, 2022

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

April 12, 2022

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

April 3, 2022

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

March 16, 2022

Supernus to Participate in Annual Cowen Health Care Conference

March 1, 2022

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

February 21, 2022

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

February 21, 2022

Calls in 2022

Decks in 2022